June 13, 2025
3 min watch
SALT LAKE CITY — On this Healio Video Perspective from the ARVO assembly, SriniVas R. Sadda, MD, FARVO, discusses a long-term examine evaluating MCO-010 for the therapy of retinitis pigmentosa.
Sadda mentioned sufferers with retinitis pigmentosa skilled sustained enhancements in visible acuity by 126 weeks after therapy with MCO-010 (Nanoscope Therapeutics). Moreover, the protection profile of the gene remedy was favorable, he mentioned.
“There are different optogenetic therapies additionally underneath analysis, which I believe displays the curiosity on this area,” he mentioned. “MCO-010 is the furthest alongside.”
Sources/Disclosures
Collapse
Sadda SR, et al. 126-week visible acuity outcomes following mutation-agnostic optogenetic remedy, MCO-010, for retinitis pigmentosa. Offered at: Affiliation for Analysis in Imaginative and prescient and Ophthalmology assembly; Could 4-8, 2025; Salt Lake Metropolis.
Disclosures:
Sadda stories consulting for Nanoscope Therapeutics.
